However, in a randomised clinical trial in which 70 patients with mild to moderate AD were treated with CoQ10 (400 mg; three times/day) for 16 weeks, no clinical benefit or significant effect on the CSF biomarkers for AD (amyloid-beta and tau protein levels) were reported [35]. The gene discussed is MAPT; the disease is Alzheimer disease.